This category covers biotechnology and pharmaceutical companies developing Protein Kinase C (PKC) modulators as neuroprotective therapies for Parkinson's disease. PKC represents a compelling target due to its central role in multiple disease-relevant pathways including alpha-synuclein phosphorylation, mitochondrial dysfunction, neuroinflammation, and autophagy-lysosomal impairment[1][2].
The PKC family comprises twelve isoforms with distinct expression patterns and functions in the brain[3]. In dopaminergic neurons of the substantia nigra pars compacta, PKC-alpha, PKC-delta, and PKC-epsilon are the most abundantly expressed, with PKC-delta driving pro-apoptotic signaling and PKC-epsilon providing neuroprotection[4]. This duality — where different isoforms have opposing effects — makes isoform-selective modulation a key therapeutic strategy[5].
Therapeutic approaches include PKC-delta inhibition (to reduce pro-apoptotic signaling, neuroinflammation, and mitochondrial dysfunction) and PKC-epsilon activation (to promote neuroprotection, mitochondrial quality control, and autophagy)[6].
PKC signaling intersects with virtually every major pathway implicated in PD pathogenesis[7]:
Alpha-synuclein phosphorylation: PKC isoforms (particularly PKC-alpha and PKC-delta) directly phosphorylate alpha-synuclein at Ser129, a modification found in >90% of alpha-synuclein in Lewy bodies. While phosphorylation promotes aggregation, the therapeutic benefit of inhibiting this modification remains under investigation.
Mitochondrial dysfunction: PKC-delta translocates to mitochondria following oxidative stress, phosphorylating Complex I subunits and reducing enzyme activity — a hallmark of sporadic PD. PKC-epsilon, in contrast, protects mitochondrial function and mediates preconditioning.
Neuroinflammation: Microglial PKC-delta activation drives NADPH oxidase activation and pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6). PKC-epsilon activation may promote anti-inflammatory (M2) microglial phenotype.
Autophagy-lysosomal dysfunction: PKC-delta activates mTORC1, inhibiting TFEB nuclear translocation and reducing autophagic flux. PKC-epsilon may enhance autophagy through mTORC1 inhibition.
Several challenges have slowed PKC-targeted therapy for PD[5:1]:
The field is shifting toward isoform-selective approaches with improved brain penetration and favorable safety profiles[8].
| Company | Candidate | Target | Indication | Stage |
|---|---|---|---|---|
| Eli Lilly | Ruboxistaurin | PKC-beta | AD/PD | Phase 2 (peripheral); preclinical (CNS) |
| Kyowa Kirin | KK-001 series | PKC pathway | PD | Discovery |
| Lundbeck | LUN-301 | PKC modulator | AD | Discovery |
| Vator Therapeutics | VT-1001 | PKC-delta | PD | Preclinical |
| Vator Therapeutics | VT-2001 | PKC-epsilon | AD/PD | Preclinical |
Zhang et al. PKC in neurodegenerative diseases. Neuropharmacology. 2023. ↩︎
Kaikkonen et al. PKC signaling in Parkinson's disease. Movement Disorders. 2022. ↩︎
Newton et al. Protein kinase C isoforms. Molecular Pharmacology. 2024. ↩︎
Mochly-Rosen et al. Localization of PKC isoforms in neurons. Neuroscience. 2024. ↩︎
Koufali & Mamalaki. PKC modulators in neurodegeneration. Current Neuropharmacology. 2023. ↩︎ ↩︎
Ferrer et al. PKC-epsilon neuroprotection in PD models. Journal of Neuroscience Research. 2023. ↩︎
Chen et al. PKC phosphorylates alpha-synuclein. Journal of Biochemistry. 2023. ↩︎
Alkon et al. Bryostatin and neuroprotection. Neuropharmacology. 2024. ↩︎